Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

Original languageEnglish (US)
Pages (from-to)119-120
Number of pages2
JournalCurrent Drug Targets: CNS and Neurological Disorders
Issue number2
StatePublished - Apr 2005


  • Acute stroke treatment
  • Infarct
  • Ischemia
  • Neuroprotectant
  • Neuroprotection
  • Repinotan

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology


Dive into the research topics of 'Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke'. Together they form a unique fingerprint.

Cite this